A phase II study reported that ceritinib, an anaplastic lymphoma kinase and ROS1 inhibitor, had efficacy in patients with ROS1-rearranged NSCLC who were previously treated with multiple chemotherapy [19]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.